Leerink Partnrs Has Positive Outlook of CMPX FY2025 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Research analysts at Leerink Partnrs raised their FY2025 earnings per share estimates for Compass Therapeutics in a note issued to investors on Wednesday, November 5th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings per share of ($0.47) for the year, up from their prior estimate of ($0.58). The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share. Leerink Partnrs also issued estimates for Compass Therapeutics’ Q4 2025 earnings at ($0.13) EPS, FY2026 earnings at ($0.58) EPS and FY2027 earnings at ($0.64) EPS.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06.

Other research analysts also recently issued research reports about the stock. Guggenheim raised their target price on shares of Compass Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, August 12th. Compass Point set a $10.00 price objective on shares of Compass Therapeutics in a research note on Monday, October 6th. D. Boral Capital restated a “buy” rating and issued a $30.00 price objective on shares of Compass Therapeutics in a report on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a report on Wednesday, October 8th. Finally, Lifesci Capital assumed coverage on Compass Therapeutics in a research report on Monday, October 6th. They set an “outperform” rating and a $10.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Compass Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $12.90.

Compass Therapeutics Stock Up 8.2%

Shares of CMPX stock opened at $4.63 on Monday. Compass Therapeutics has a 12 month low of $1.27 and a 12 month high of $4.86. The company’s fifty day simple moving average is $3.82 and its 200-day simple moving average is $3.02. The firm has a market cap of $640.24 million, a PE ratio of -10.29 and a beta of 1.48.

Institutional Investors Weigh In On Compass Therapeutics

Several hedge funds have recently bought and sold shares of CMPX. Creative Planning bought a new position in Compass Therapeutics during the second quarter worth about $30,000. Strs Ohio bought a new stake in Compass Therapeutics in the first quarter valued at approximately $34,000. Apollon Wealth Management LLC acquired a new stake in shares of Compass Therapeutics in the third quarter valued at approximately $35,000. Birchview Capital LP acquired a new stake in shares of Compass Therapeutics in the first quarter valued at approximately $46,000. Finally, Walleye Trading LLC bought a new position in shares of Compass Therapeutics during the 1st quarter worth approximately $48,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.